TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03714802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Szabo T-Stenting Technique
Description: 2-stent strategy was performed using modified T-stenting with Szabo technique in bifurcation lesions. First, stent was implanted in the side branch with Szabo technique. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Szabo T-Stenting Technique
Description: 2-stent strategy was performed using modified T-stenting with Szabo technique in bifurcation lesions. First, stent was implanted in the side branch with Szabo technique. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-Stenting Technique
Description: 2-stent strategy was performed using traditional T-stenting technique in bifurcation lesions. First, stent was implanted in the side branch with angiographic guidance. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: T-Stenting Technique
Description: 2-stent strategy was performed using traditional T-stenting technique in bifurcation lesions. First, stent was implanted in the side branch with angiographic guidance. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
Study: NCT04654936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIND diet with no support
Description: Participants are to consume MIND diet food recommendations over a 12 week period with no support except for a self-monitoring resource and MIND diet guidelines
Study: NCT04705857

Intervention type: COMBINATION_PRODUCT
Intervention: Histograft, a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene
Description: gene-activated bone substitute in granular form, concentration of the plasmid DNA is 100 μg per 1.0 g of the OCP scaffold
Study: NCT04585035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553
Description: D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553
Description: D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
Study: NCT03230591

Intervention type: OTHER
Intervention: Echocardiography
Description: LV vortex flow in Echocardiography
Study: NCT03563053

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EryDex System
Description: EryDex System was a combination product that was used to load dexamethasone sodium phosphate (DSP) into autologous erythrocytes (EDS) creating the EDS-end product which was infused into the patients.~EryDex treatment consisted of a dose range correspondent to the ATTeST High Dose (obtained by loading 125 mg of DSP to the EryDex process and that, in the ATTeST, resulted in a mean of 17.4 ± 5.4 mg (mean ± standard deviation) of DSP infused to patients) administered via ex vivo encapsulation into EDS that were infused into the patient with A-T.~The dose of EryDex treatment was selected to allow collection of long-term safety data on the dose of erythrocyte encapsulated DSP that was considered more effective among the two different doses that were employed in the ATTeST study, based on the analysis of the ATTeST blinded, Phase 3 study data.
Study: NCT03519373

Intervention type: BIOLOGICAL
Intervention: TDaP
Description: Tetanus, Diphteria and Acellular Pertussis vaccine (Boostrix)
Study: NCT03788369

Intervention type: PROCEDURE
Intervention: Hybrid Coronary Revascularization
Description: Hybrid coronary revascularization (HCR) combines minimally invasive surgical coronary artery bypass grafting of the left anterior descending artery with percutaneous coronary intervention (PCI) of non-left anterior descending vessels.
Study: NCT03519373

Intervention type: BIOLOGICAL
Intervention: TDaP
Description: Tetanus, Diphteria and Acellular Pertussis vaccine (Boostrix)

Intervention type: BIOLOGICAL
Intervention: TDaP
Description: Tetanus, Diphteria and Acellular Pertussis vaccine (Boostrix)
Study: NCT03722446

Intervention type: DEVICE
Group type: OTHER
Intervention: Arrow Catheter Kit.
Description: The group will be randomized to receive this labor analgesia kit.

Intervention type: DEVICE
Group type: OTHER
Intervention: B.Braun Catheter Kit
Description: The group will be randomized to receive this labor analgesia kit.
Study: NCT04585035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553
Description: D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other
Description: Standard treatment of solid tumor, NSCLC or CRC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other
Description: Standard treatment of solid tumor, NSCLC or CRC
Study: NCT02758626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ataluren
Description: Powder formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ataluren
Description: Powder formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Powder formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Powder formulation
Study: NCT00283166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Education and Coaching
Description: A: Patients receive one-on-one counseling and education about pain management and improving doctor-patient communication B: Patients receive booklet on cancer pain control

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tailored Education and Coaching
Description: A: Patients receive one-on-one counseling and education about pain management and improving doctor-patient communication B: Patients receive booklet on cancer pain control
Study: NCT02371187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin tablets, 5 mg, one per day for the first 14 days, increase to two per day for 70 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for Dapagliflozin 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
Study: NCT01208766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib, Melphalan, Prednisone (VMP)
Description: * Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11,22,25,29,32~* Melphalan _ 9 mg/m² _ p.o. _ days 1-4~* Prednisone _ 60 mg/m² _ p.o. _ days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 or 2 cycle(s) HDM (High Dose Melphalan)
Description: - Melphalan _ 100 mg/m² _ i.v. rapid infusion _ -3, -2\*~\*Patients with renal insufficiency 100 mg/m2 only at day -3~If a patient is randomized to receive 2 x HDM a second course of High Dose Melphalan may be administered between 2 and 3 months after the first course when the patient achieved at least PR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)
Description: * Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11~* Lenalidomide _ 25 mg _ p.o. _ days 1-21~* Dexamethasone _ 20 mg _ p.o. _ days 1,2,4,5,8,9,11,12
Study: NCT02730169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGS649
Description: Capsules were taken weekly for a maximum of 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGS649
Description: Capsules were taken weekly for a maximum of 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGS649
Description: Capsules were taken weekly for a maximum of 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules were taken weekly for a maximum of 24 weeks
Study: NCT00643656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kalinox 170 bar
Description: Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mix of 50% oxygen and 50% nitrogen
Description: Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
Study: NCT04501120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG-2575 orally once daily, every 28 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG-2575 orally once daily, every 28 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG-2575 orally once daily, every 28 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG-2575 orally once daily, every 28 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG-2575 orally once daily, every 28 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced-dose HHT
Description: 1mg IV QD on Days 1-14 (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard-dose HHT
Description: 2mg/m\^2 IV QD on Days 1-7 (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG-2575 orally once daily for 14 days, every 28 days as a cycle.
Study: NCT00928720

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CES device
Description: Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham device
Description: The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
Study: NCT02826785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive strategy training
Description: The intervention teaches strategies in a way that promotes generalization and enhances daily function . It includes four core elements known to enhance learning transfer: (1) self-generation of broadly applicable strategies, (2) practice across multiple contexts and activities, (3) emphasis on metacognition, and (4) use of meaningful everyday activities.
Study: NCT00237159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT03941561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 for 9 months
Description: S-1 for 9 months after D2 resection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1 for 1 year
Description: S-1 for 1 year after D2 resection
Study: NCT03747237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Edema measurement methods
Description: A correlation between the results of the first and second methods will be examined.
Study: NCT04031950

Intervention type: DEVICE
Intervention: Novel wearable paediatric device
Description: The patient will wear the novel wearable paediatric device at the same time as polysmnography

Intervention type: DEVICE
Intervention: Novel wearable paediatric device
Description: The patient will wear the novel wearable paediatric device at the same time as polysmnography
Study: NCT00738660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan, Ramipril
Description: 80 mg of telmisartan administered for 8weeks,followed by addition of ramipril 10 mg for further 8weeks
Study: NCT01767987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Oral dose twice per day for 3 days leading up to PCI
Study: NCT02102945

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Computed tomography perfusion
Description: Computed tomography perfusion of the head
Study: NCT06335212

Intervention type: DEVICE
Intervention: Single vision and multifocal contact lenses
Description: Cycloplegic central autorefraction was conducted with both Grand Seiko WAM-5500 open-field auto-refractor (Grand Seiko Co Ltd) and OPD OPD-Scan III Wavefront Aberrometer (Marco) on the subjects in the following conditions: (1) no CLs, (2) SVCLs, (3) MFCLs (+2.00D Add), and (4) MFCLs (+4.00D Add). Relative peripheral power profiles were measured using the OPD under the same 4 conditions after cycloplegia.
Study: NCT03005002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT02266771

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPWT with Instillation
Description: Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System with V.A.C. VeraFlo Instillation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NPWT
Description: Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System
Study: NCT03380273

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation of the AO Trauma SSI Prevention Bundle
Description: AOT SSI Prevention Bundle~Preventive measure~1. Antibiotic prophylaxis~2. Perioperative antibiotics~3. Oxygen administration~4. Patient temperature~5. Surgeon protective wear~6. Patient operative skin preparation~7. Suction drains~8. Blood glucose level~9. Red cell transfusion~10. Dressing changes
Study: NCT03741855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cloud Dx Kit with self-monitoring
Description: Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cloud Dx Kit with remote-monitoring
Description: * Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.~* A respiratory therapist (RT) will be monitoring asynchronously patient vitals and contacting them when their vitals exceed pre-determined thresholds.~* The RT will also check on patients once a week irrespective of the value of the vitals.
Study: NCT03809533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir/velpatasvir
Description: 12-week, oral, fixed-dose
Study: NCT00263627

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
Study: NCT04479748

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Treatment of pain and inflammation following ophthalmic surgery

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone Acetate 1% Oph Susp
Description: Topical steroid
Study: NCT01559558

Intervention type: PROCEDURE
Intervention: vaginal packing
Description: vaginal packing after urodynamic studies, and repeat urethral pressure profile
Study: NCT01680016

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zagreb
Description: Subjects received Zagreb schedule (2-1-1) i.e. 4 vaccinations of Rabipur at days 1 , 8 and 22

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zagreb
Description: Subjects received Zagreb schedule (2-1-1) i.e. 4 vaccinations of Rabipur at days 1 , 8 and 22

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Essen
Description: Subjects received Essen schedule (1-1-1-1-1) i.e. 5 vaccinations of Rabipur at days 1, 4, 8, 15 and 29

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Essen
Description: Subjects received Essen schedule (1-1-1-1-1) i.e. 5 vaccinations of Rabipur at days 1, 4, 8, 15 and 29
Study: NCT03602027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 8mg p.o. qd in low-dose groups (3 subjects). 10mg p.o. qd in middle-dose groups (3 subjects). 12mg p.o. qd in high-dose groups (3 subjects).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg orally daily for three weeks
Study: NCT02064140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Study: NCT00223938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron
Description: Oral Iron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium ferric gluconate
Description: weekly intravenous injection Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium ferric gluconate
Description: weekly intravenous injection Dose 2
Study: NCT03139721

Intervention type: DEVICE
Intervention: Mosaic model 305, model 310, and ultra model 305
Description: Aortic or mitral valve replacement
Study: NCT03235986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I)
Description: Single ascending doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part I)
Study: NCT01779375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Study: NCT01268761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (Cetrorelix)
Description: •GnRH antagonist (Cetrorelix 0.25) during 7 days beginning administration the second day of oocyte retrieval

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline solution)
Description: • Placebo (saline solution) 1 ampoule every 24 hours during 7 days beginning administration the second day of oocyte retrieval
Study: NCT01773122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Formulation A
Description: Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
Study: NCT03235986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II)
Description: Two doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part II)

Intervention type: OTHER
Group type: OTHER
Intervention: nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I)
Description: Nasal continuous positive airway pressure alone

Intervention type: OTHER
Group type: OTHER
Intervention: nCPAP (nasal Continuous Positive Airway Pressure) alone (Part II)
Description: nasal continuous positive airway pressure alone
Study: NCT01688882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 will be evaluated at various dose levels and regimens, based on the impact on disease of the next highest dose level and regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 will be evaluated at various dose levels and regimens, based on the impact on disease of the next highest dose level and regimen.
Study: NCT01773122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Formulation B
Description: Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Formulation C
Description: Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone 5% Gel
Description: Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
Study: NCT01688882

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be used to control for normal variability in disease severity.
Study: NCT04316325

Intervention type: DRUG
Intervention: Medical abortion
Description: Trained abortion providers will counsel participants about medical abortion via videoconference or telephone, the abortion medications will be sent to the participants via mail or will be accessed at a pharmacy, the provider will follow up one week later with the participants to assess outcomes, and four weeks later the participant will take a pregnancy test to confirm completion of the abortion
Study: NCT03701126

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plane Block
Description: ultrasound (US) guided TAP block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Block
Description: ultrasound (US) guided caudal block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
Study: NCT03517605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise for cardiac rehabilitation
Description: An exercise program was designed according to the American College of Sports Medicine and performed by the Specialist Nurses in Rehabilitation Nursing. Comprises aerobic and recovery/stretching. Started in the intensive care unit after the 24 hours post-surgery, and later, during hospitalization. Clinical data (Blood Pressure, Heart Rate, Peripheral Oxygen Saturation) and Borg scale will be recorded in the initial, intermediate and final periods of each session. Capillary glycemia will be evaluated at the beginning of each session. Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided in heating (10-25 min), aerobic exercise (10 min) and recovery (10-25min). Possible symptoms will be controlled during exercise sessions.